For example, the mutation rate of EGFR in non-small-cell lung cancer is 16–18% in North Americans and Europeans, 19% in African-Americans, 22% in Indians, 29% in Koreans, 40% in Japanese, and around 50% in Chinese [31]; such variability in EGFR mutation rate led to different effectiveness of tyrosine kinase inhibitors in the given population. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.